Home › Glaucoma › NCT04967989

Clarifying the Optimal Application of SLT Therapy Trial

RecruitingPhase 3

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

1. Age 18 or older and in good health
2. Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):

1. High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes)
2. Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation better than -6.0 dB with no points in the central 5° \<15 dB (see figure on next page)
3. Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5° points \<15 dB or mean deviation -12.0 dB or better with 1 central 5° points \<15 dB (see figure on next page).
3. Each eye with BCVA 20/200 (UK 6/60) or better

Exclusion Criteria:

1. Use of topical IOP-lowering medications for more than 6 cumulative months at any time in the past 5 years (this is a modification implemented during active enrollment)
2. Any history of IOP-lowering laser (prophylactic iridotomy not included) or surgical procedure
3. Advanced POAG in either eye (worse than moderate POAG as defined above)
4. Glaucoma other than POAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
5. Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
6. Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
7. Contraindications to SLT or any other study intervention
8. Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
9. Any intraocular surgical procedure within the past 6 months in either eye
10. Inability to attend all scheduled study visits
11. Pregnant or planning to become pregnant in the next 4 years

About the study

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

What is being tested

Low Energy SLT (procedure)
Standard Energy SLT (procedure)

Sponsor: University of Pittsburgh · Participants: 790 · Started: Sep 7, 2021

Contact the study team

Tony Realini, MD, MPH · Phone: 3045986926

Official record on ClinicalTrials.gov — NCT04967989

Locations in the U.S.

California	Harvard Eye Associates, Laguna Hills Doheny Eye Center UCLA, Pasadena University of California, Davis, Sacramento University of California, San Francisco, San Francisco
Colorado	Mile High Eye Institute, Sheridan
Florida	Clear Vue Laser Eye Center, Lakeworth
Illinois	Northwestern Medical Group, Chicago Chicago Arbor Eye Institute, Orland Park Illinois Eye Center, Peoria
Maryland	Wilmer Eye Institute Johns Hopkins, Baltimore
Massachusetts	Massachusetts Eye and Ear, Boston Ophthalmic Consultants of Boston, Boston Mark Latina, LLC, Reading
Michigan	University of Michigan Kellogg Eye Center, Ann Arbor Kresge Eye Institute Wayne State University, Detroit
New York	New York Eye Surgery Associates, The Bronx
Ohio	Cleveland Clinic Cole Eye Institute, Cleveland University Hospitals Eye Institute, Cleveland
Oregon	Devers Eye Institute, Portland
Pennsylvania	Eye Care Specialists, Kingston Scheie Eye Institute, Philadelphia Wills Eye Hospital, Philadelphia
Tennessee	Vanderbilt Eye Institute, Nashville
Texas	Ophthalmology Associates, Fort Worth
Washington	Spokane Eye Clinical Research, Spokane
West Virginia	West Virginia University, Morgantown
Wisconsin	University of Wisconsin-Madison, Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.